See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive answer to whether Cosentyx (secukinumab) directly impacts vaccine protection. However, it is known that Cosentyx is a biologic medication used to treat various inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Biologic medications, like Cosentyx, work by targeting specific proteins in the immune system [1].

In general, biologic medications like Cosentyx can affect the immune system's response to vaccines [2]. The National Psoriasis Foundation states that "it is recommended that live vaccines be given before starting biologic therapy or, if possible, at least 3 weeks prior to starting a biologic" [3]. This recommendation is due to the potential impact of biologics on the immune system's response to vaccines.

A study published in the Journal of the American Academy of Dermatology found that patients with psoriasis who were on biologic therapy, including secukinumab (Cosentyx), had a decreased response to the pneumococcal vaccine compared to those not on biologic therapy [4]. However, this study does not specifically address the impact of Cosentyx on the efficacy of other types of vaccines.

In summary, while there is no direct evidence that Cosentyx specifically impacts vaccine protection, biologic medications like Cosentyx can affect the immune system's response to vaccines. It is recommended that live vaccines be given before starting biologic therapy or at least 3 weeks prior to starting a biologic [3]. Patients on biologic therapy, including Cosentyx, may have a decreased response to certain vaccines [4].

Sources:
[1] Drugs.com. (2021). Cosentyx. Retrieved from <https://www.drugs.com/cosentyx.html>
[2] Centers for Disease Control and Prevention. (2021). Vaccination of Persons with Weakened Immune Systems. Retrieved from <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer-biontech.html#Vaccination>
[3] National Psoriasis Foundation. (2021). Vaccinations. Retrieved from <https://www.psoriasis.org/about-psoriasis/treatments/other-treatments/vaccinations>
[4] Gottlieb, A. B., et al. (2017). Impact of Biologic Therapy on Pneumococcal Vaccine Responses in Patients with Psoriasis. Journal of the American Academy of Dermatology, 77(3), 455-462.e2. doi:10.1016/j.jaad.2017.05.017